Related Experiment Video
Updated: Nov 8, 2025
09:09
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
6.2K
Reduction-Responsive Anticancer Nanodrug Using a Full Poly(ethylene glycol) Carrier.
Qiuquan Cai1, Jiahong Jiang2, Hongjie Zhang1
1MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China.
ACS Applied Materials & Interfaces
|April 20, 2021
Summary
This study introduces a novel, fully poly(ethylene glycol) (PEG) nanodrug carrier for hydrophobic anticancer drugs. The nanodrug demonstrates enhanced stability, targeted drug release in tumors, and improved in vivo antitumor efficacy with reduced side effects.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery
Background:
- Poly(ethylene glycol) (PEG) is widely used in biomedicine due to its biocompatibility.
- PEG's hydrophilicity hinders its self-assembly into micelles for hydrophobic drug delivery.
- Developing effective carriers for hydrophobic anticancer drugs remains a challenge.
Purpose of the Study:
- To synthesize a novel amphiphilic PEG derivative for nanodrug formulation.
- To create a self-assembled nanodrug carrier for paclitaxel (PTX).
- To evaluate the nanodrug's stability, targeted release, and in vivo efficacy.
Main Methods:
- Synthesis of an amphiphilic PEG derivative via melt polycondensation.
- Preparation of PTX-loaded nanodrugs through self-assembly.
- Assessment of nanodrug stability, drug release kinetics, and in vivo antitumor activity.
Main Results:
- A stable, full-PEG nanodrug carrier was successfully fabricated.
- The nanodrug exhibited selective disassociation and PTX release in a reductive tumor microenvironment.
- In vivo studies showed prolonged circulation time, significant antitumor efficacy, and reduced toxicity.
Conclusions:
- The developed nanodrug carrier offers a promising platform for delivering hydrophobic anticancer agents.
- Targeted drug release and improved biocompatibility address key challenges in cancer therapy.
- This approach holds potential for treating various malignant tumors with enhanced safety.
